Clinical Trial Detail

NCT ID NCT02119650
Title Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium + Ruxolitinib

Cisplatin + Pemetrexed Disodium

Age Groups: adult

No variant requirements are available.